France Diabetes Care Devices Market Outlook to 2025 - Glucose Monitoring and Insulin Delivery

Table of Contents

• 1.1 List of Tables 5
• 1.2 List of Figures 5

2 Introduction 7

• 2.1 What Is This Report About? 7
• 2.2 Diabetes Care Devices Market Segmentation 7
• 2.3 Definitions of Markets Covered in the Report 8

3 Diabetes Care Devices Market, France 10

• 3.1 Diabetes Care Devices Market, France, Revenue ($m), 2015-2025 10
• 3.2 Diabetes Care Devices Market, France, Revenue Mix ($m), 2019 12
• 3.3 Diabetes Care Devices Market, France, Category Contribution by Revenue ($m), 2019 13
• 3.4 Diabetes Care Devices Market, France, Revenue ($m), 2015-2025 14
• 3.5 Diabetes Care Devices Market, France, Volume (Units), 2015-2025 16
• 3.6 Diabetes Care Devices Market, France, Volume (Units), 2015-2025 18
• 3.7 Diabetes Care Devices Market, France, Company Share by Revenue ($m), 2019 20

4 Glucose Monitoring Market, France 22

• 4.1 Glucose Monitoring Market, France, Revenue ($m), 2015-2025 22
  • 4.1.1 Blood Glucose Meters Market, France, Revenue ($m), by Segment, 2015-2025 24
• 4.2 Glucose Monitoring Market, France, Volume (Units), 2015-2025 26
  • 4.2.1 Blood Glucose Meters Market, France, Volume (Units), by Segment, 2015-2025 28
• 4.3 Glucose Monitoring Market, France, Average Price ($) , 2015-2025 30
• 4.4 Glucose Monitoring Market, France, Distribution Share by Revenue ($m), 2019 31
• 4.5 Glucose Monitoring Market, France, Company Share by Revenue ($m), 2019 32

5 Insulin Delivery Market, France 33

• 5.1 Insulin Delivery Market, France, Revenue Mix ($m), 2019 33
• 5.2 Insulin Delivery Market, France, Segment Contribution (%), 2019 34
• 5.3 Insulin Delivery Market, France, Revenue ($m), 2015-2025 35
  • 5.3.1 Insulin Pens Market, France, Revenue ($m), by Segment, 2015-2025 37
  • 5.3.2 Insulin Pumps Market, France, Revenue ($m), by Segment, 2015-2025 39
• 5.4 Insulin Delivery Market, France, Volume (Units), 2015-2025 41
  • 5.4.1 Insulin Pens Market, France, Volume (Units), by Segment, 2015-2025 43
  • 5.4.2 Insulin Pumps Market, France, Volume (Units), by Segment, 2015-2025 45
• 5.5 Insulin Delivery Market, France, Average Price ($), 2015-2025 47
• 5.6 Insulin Delivery Market, France, Distribution Share by Revenue ($m), 2019 48
• 5.7 Insulin Delivery Market, France, Company Share by Revenue ($m), 2019 49

6 Overview of Key Companies in France, Diabetes Care Devices Market 51

• 6.1 DexCom Inc 51
  • 6.1.1 Company Overview 51
• 6.2 Medtronic Plc 51
  • 6.2.1 Company Overview 51
• 6.3 Abbott Laboratories 51
  • 6.3.1 Company Overview 51
• 6.4 Novo Nordisk AS 52
  • 6.4.1 Company Overview 52
• 6.5 Sanofi 52
  • 6.5.1 Company Overview 52
• 6.6 Eli Lilly and Co 52
  • 6.6.1 Company Overview 52
• 6.7 F. Hoffmann-La Roche Ltd 53
  • 6.7.1 Company Overview 53
• 6.8 Ypsomed Holding AG 53
  • 6.8.1 Company Overview 53

7 Diabetes Care Devices Market Pipeline Products 54

8 Financial Deals Landscape 55

• 8.1 Debt Offerings 55
  • 8.1.1 Sanofi Prices Public Offering of 1.000% Notes Due 2025 for USD804.8 Million 55
  • 8.1.2 Sanofi Prices Public Offering of 1.500% Notes Due 2030 for USD804.8 Million 56
• 8.2 Equity Offerings 57
  • 8.2.1 Beurer Invests USD2.51 Million in PKvitality 57
• 8.3 Partnerships 58
  • 8.3.1 Biocorp Production Enters into Agreement with Amalgam Rx (iSage Rx) 58
  • 8.3.2 Sanofi and Abbott Enter into Partnership 59
  • 8.3.3 LifeScan Enters into Distribution Agreement with Sanvita Medical 60
  • 8.3.4 Diabeloop and ViCentra Enter into Distribution Agreement 61
• 8.4 Venture Financing 62
  • 8.4.1 Diabeloop Raises USD34 Million in Series B Financing 62

9 Recent Developments 64

• 9.1 Corporate Communications 64
  • 9.1.1 Mar 04, 2020: Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors 64
  • 9.1.2 Feb 25, 2020: Sanofi announces resignation of Director 65
  • 9.1.3 Dec 04, 2019: Duke Health: New, non-hormonal target identified for advanced prostate cancer 65
  • 9.1.4 Oct 15, 2019: Northwell Health extends partnership with comprehensive Allscripts Sunrise platform through 2027 66
  • 9.1.5 Jul 29, 2019: Sanofi: Appointment of additional director and whole time director 67
  • 9.1.6 Jul 26, 2019: Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer 67
  • 9.1.7 Jun 07, 2019: Paul Hudson to succeed Olivier Brandicourt as chief executive officer 68
  • 9.1.8 Apr 09, 2019: Voluntis appoints Berkley Nelson as Chief Growth Officer 69
• 9.2 Financial Announcements 69
  • 9.2.1 Feb 06, 2020: Sanofi delivers strong 2019 business EPS growth of 6.8% at CER 69
  • 9.2.2 Jan 27, 2020: Theraclion demonstrates its leadership in thyroid and veins none invasive treatments 79
  • 9.2.3 Oct 31, 2019: Sanofi Q3 well on track 80
  • 9.2.4 Oct 17, 2019: The Bristol-Myers Squibb-Pfizer alliance and Fitbit collaborate to address gaps in Atrial Fibrillation Detection with the aim of accelerating diagnosis 83
  • 9.2.5 Sep 19, 2019: Voluntis reports business review and financial results for first half of 2019 85
  • 9.2.6 Sep 16, 2019: Theraclion: Half year results 2019 87
  • 9.2.7 Jul 29, 2019: Sanofi delivered solid growth in Q2 2019 88
  • 9.2.8 Jul 22, 2019: Growth in first half 2019 sales of Theraclion SA: + 12% 97
  • 9.2.9 May 15, 2019: Atara Biotherapeutics announces presentations highlighting Mesothelin-Targeted CAR T clinical results at American Society of Clinical Oncology (ASCO) Annual Meeting 98
• 9.3 Legal And Regulatory 99
  • 9.3.1 Oct 03, 2019: Lilly announces voluntary delisting from Euronext Paris 99
  • 9.3.2 Sep 30, 2019: Adocia announces receipt of USD 14.3 million payment from Eli Lilly following arbitration conclusion and the decision by mutual consent with Eli Lilly to conclude the civil case 101
  • 9.3.3 Aug 23, 2019: Adocia announces that the American Arbitration Association Tribunal Dismissed all Claims in Second Phase of Arbitration With Eli Lilly 101
• 9.4 Other Significant Developments 102
  • 9.4.1 Jan 14, 2020: BIOCORP and SANOFI strengthen their partnership with Mallya Smart Sensors 102
  • 9.4.2 Jun 19, 2019: Gamida Cell and Lonza establish commercial manufacturing agreement for omidubicel 102
  • 9.4.3 Apr 26, 2019: Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER 103
  • 9.4.4 Apr 10, 2019: Sanofi provides unprecedented access to its insulins for one set monthly price 110
• 9.5 Research And Development 111
  • 9.5.1 Sep 13, 2019: Aimmune stock trading halted; FDA Allergenic Products Advisory Committee (APAC) meeting to discuss PALFORZIA (AR101) for Peanut Allergy 111
• 9.6 Strategy And Business Planning 111
  • 9.6.1 Oct 15, 2019: Sanofi opens digital manufacturing facility in the US 111
  • 9.6.2 May 21, 2019: Verily forms strategic alliances with Novartis, Otsuka, Pfizer and Sanofi to transform clinical research 112

10 Appendix 115

• 10.1 Research Methodology 116
  • 10.1.1 Coverage 116
  • 10.1.2 Secondary Research 116
  • 10.1.3 Primary Research 117
  • 10.1.4 Market Modeling and Forecasting 117
  • 10.1.5 Company Share Analysis 119
  • 10.1.6 Distribution Share Analysis 119
  • 10.1.7 Benchmarking 120
• 10.2 GlobalData Consulting 120
• 10.3 Contact Us 121